Jam Irandokht Nikbakht, Sahebkar Amir Hossein, Eslami Saeid, Mokhber Naghmeh, Nosrati Mina, Khademi Mohammad, Foroutan-Tanha Mojtaba, Ghayour-Mobarhan Majid, Hadizadeh Farzin, Ferns Gordon, Abbasi Masoumeh
Metabolic Research Center, School of Medicine, Mashhad University of Medical Sciences, Iran.
Biotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Iran.
Adv Clin Exp Med. 2017 Sep;26(6):925-930. doi: 10.17219/acem/62891.
Studies have suggested that metabolic syndrome (MetS) is associated with increased depressive symptoms, and reducing depression in subjects with MetS is important. Crocin, an active component of saffron, has useful properties for subjects with MetS, including antidepressant properties.
The aim of the study was to assess the effect of a preparation of crocin on the symptoms of depression in subjects with MetS, and the relationship between changes in those symptoms and the serum pro-oxidant/anti-oxidant balance (PAB).
This sub-study was carried out on 34 subjects with MetS from the authors' previous randomized double-blind controlled clinical trial (RCT), all of whom met the inclusion criteria for this study. The subjects were randomly assigned to treatment and placebo groups (n = 17 in each group) and received each 30 mg of crocin (2 tablets of 15 mg) or placebo for 8 weeks. Depressive symptoms were assessed using the Beck Depression Inventory (BDI). The BDI questionnaire was completed for each subject at the baseline and at the end of the 8th week of treatment. Blood samples were taken from the subjects before and after the intervention period. Statistical analyses were performed using the SPSS for Windows, v. 16 (SPSS Inc., Chicago, USA).
Out of the 34 participants enrolled, 33 completed the trial. The degree of depression decreased significantly in the crocin group (p = 0.005), but not in the placebo group (p > 0.05), and the difference between the 2 groups was statistically significant (p = 0.013). No significant relationship was observed between changes in depression symptoms and changes in the serum PAB (p > 0.05).
This study demonstrates that at a dose of 30 mg per day for 8 weeks, crocin reduced the symptoms of depression in subjects with MetS compared to the control group, and this effect was independent of its effect on the serum PAB.
研究表明，代谢综合征（MetS）与抑郁症状增加有关，减轻MetS患者的抑郁症状很重要。藏红花的活性成分西红花苷对MetS患者具有有益特性，包括抗抑郁特性。
本研究旨在评估西红花苷制剂对MetS患者抑郁症状的影响，以及这些症状变化与血清促氧化剂/抗氧化剂平衡（PAB）之间的关系。
本亚研究对作者之前的随机双盲对照临床试验（RCT）中的34名MetS患者进行，所有患者均符合本研究的纳入标准。受试者被随机分为治疗组和安慰剂组（每组n = 17），并分别接受30 mg西红花苷（2片15 mg）或安慰剂，持续8周。使用贝克抑郁量表（BDI）评估抑郁症状。在基线和治疗第8周结束时，为每位受试者完成BDI问卷。在干预期前后采集受试者的血样。使用Windows版SPSS 16.0（SPSS公司，美国芝加哥）进行统计分析。
在纳入的34名参与者中，33名完成了试验。西红花苷组的抑郁程度显著降低（p = 0.005），而安慰剂组未降低（p > 0.05），两组之间的差异具有统计学意义（p =
